Skip to main content
Fig. 2 | AIDS Research and Therapy

Fig. 2

From: Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study

Fig. 2

A Changes in Uβ2MG (median ± interquartile range: IR) of the patients switching from TDF to TAF. B Changes in Uβ2MG (median ± interquartile range: IR) of the patients switching from TDF to TAF. TAF: tenofovir alafenamide fumarate; TAF0: start of TAF; TAF12, -24, -48, -96 and -144: 12 weeks, 24 weeks, 48 weeks, 96 weeks and 144 weeks after starting TAF. *p < 0.05 is defined as a significant difference by the Wilcoxon rank sum test between groups. †p < 0.05 is defined as a significant difference by Wilcoxon signed rank test for G1 group. ‡p < 0.05 is defined as significant differences by the Wilcoxon signed rank test for the G2 group. §p < 0.05 is defined as significant differences by the Wilcoxon signed rank test for the G3a and G3b groups

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us